Dipeptidyl Peptidase-4 Link With Oral Cancer and Premalignant Lesions

Fayoum University

Status: Completed

Conditions: Oral Premalignant Lesions as Leukoplakia and Lichen Planus; Oral Cancer

Treatments: Diagnostic Test: serum and unstimulated salivary samples

Study type: Observational

Funder types: Other

Identifiers

NCT06087042

: IRB00012891#77

Details and patient eligibility

About

Aim: The current study targets linking serum and salivary dipeptidyl peptidase-4 with oral squamous cell carcinoma and comparing it with potentially malignant lesions and control to validate dipeptidyl peptidase-4 as a diagnostic marker for early detection of oral cancer and to reveal its possible role in carcinogenesis.

Methodology: A total of 45 patients were recruited and subdivided into 2 groups: Group I: 15 patients having oral squamous cell carcinoma. Group II: 15 patients with potentially malignant lesions (leukoplakia and oral lichen planus) compared to 15 systemically healthy participants having no oral mucosal lesions acting as a control group (Group III). Serum and whole unstimulated salivary samples were collected from all participants to evaluate dipeptidyl peptidase level in different groups using enzyme linked immune-sorbent assay (ELISA) kit. ROC analysis was done to reveal area under the curve, sensitivity, specificity and diagnostic accuracy of DPP-4 among different groups.

Enrollment: 45 patients

Sex: All

Ages: 30 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• systemically healthy
• No current medication,
• both genders with age ranging from 30 to 65 years old.
• having oral leukoplakia, oral lichen planus or oral squamous cell carcinoma

Exclusion criteria

• systemic disease
• pregnancy
• lactation
• being diagnosed with any other oral mucosal lesion

Trial design

45 participants in 3 patient groups

Group I

Description:

patients suffering from oral squamous cell carcinoma

Treatment:

Diagnostic Test: serum and unstimulated salivary samples

Group II

Description:

patients diagnosed with potentially malignant lesions such as leukoplakia, and dysplastic erosive or atrophic oral lichen planus

Treatment:

Diagnostic Test: serum and unstimulated salivary samples

Group III

Description:

individuals with no oral mucosal lesions

Treatment:

Diagnostic Test: serum and unstimulated salivary samples